Peptides and insurance coverage — what's covered, what isn't, and why

Insurance coverage for any drug follows three linked decisions made before you ever ask for reimbursement. First, the FDA has to have approved the drug. Second, your plan's pharmacy benefit manager — the company that actually administers your prescription benefit — has to have placed that drug on their formulary, which is their tiered list of covered medications. Third, the drug has to be prescribed for an indication that either appears on the FDA label or has been accepted by your specific plan for coverage. All three gates have to be open simultaneously. Miss any one of them and coverage disappears regardless of how well-documented your medical need is.

FDA-approved peptides prescribed for their approved indications sit in the best position. Semaglutide prescribed for type 2 diabetes has been covered by most commercial insurance since shortly after Ozempic's approval in 2017. Tirzepatide for type 2 diabetes followed a similar path after its 2022 approval. Liraglutide for type 2 diabetes has been on formularies for years. Growth hormone therapy for documented growth hormone deficiency — confirmed by two provocative stimulation tests plus clinical criteria — is typically covered under medical benefits, though prior authorization is nearly universal and your prescriber will need to submit labs, growth velocity data in children, or adult-onset deficiency documentation. Vyleesi, the bremelanotide injection for hypoactive sexual desire disorder in premenopausal women, is FDA-approved for that specific indication but coverage varies significantly by plan; prior authorization is common and some plans exclude it. The pattern holds across all of these: approval plus matching indication equals a real conversation with your insurer, even if that conversation involves paperwork.

FDA-approved peptides prescribed off-label are a different category entirely. Semaglutide for obesity was an off-label use before Wegovy's 2021 approval, and many physicians used it that way. Without the matching FDA indication, coverage was nearly impossible. Even after Wegovy's approval, many plans initially excluded weight loss drugs as a category — a separate benefit exclusion that applied regardless of FDA approval status. That exclusion has eroded somewhat as the clinical evidence around GLP-1 drugs and cardiovascular outcomes has grown, and some employers have added obesity drug coverage in recent years. But the baseline is still that off-label use of approved peptides means you're in prior authorization territory at best, and those authorizations get denied more often than they're approved without a well-documented appeal.

Compounded peptides occupy a category where insurance coverage is almost nonexistent. Compounding pharmacies operate under a specific legal framework — 503A for patient-specific prescriptions — that exists outside the FDA drug approval process. The drug benefit your insurer administers is built around FDA-approved products placed on formulary. A compounded medication isn't an FDA-approved product; it's a preparation made for a specific patient by a licensed pharmacy. Most pharmacy benefit managers have no mechanism to adjudicate compounded medications at all, because they were never submitted for formulary placement. The absence of coverage isn't a bias against peptides specifically — compounded formulations of many drugs face the same wall. The clinical value of a compounded preparation is simply invisible to the benefit structure.

The semaglutide compounding situation became particularly charged in 2024. While semaglutide remained on the FDA drug shortage list, compounding pharmacies were permitted under specific regulatory guidance to prepare compounded semaglutide — a significant access route given Ozempic and Wegovy supply constraints. When the FDA removed semaglutide from the shortage list in early 2024, that regulatory basis for compounding largely closed. The FDA has since taken enforcement action against compounding operations continuing to prepare semaglutide without adequate basis. The politics here are real: GLP-1 drugs at brand prices are inaccessible for many patients, and compounding represented a lower-cost access path. That path has narrowed significantly, and the regulatory trend is toward stricter enforcement rather than looser. Whether you agree with that outcome depends on how you weigh access against quality control, but understanding the current legal reality affects how you approach sourcing.

Research peptides — those sold as reference compounds or for laboratory use — exist entirely outside any insurance framework. They are not medications. They are not dispensed by pharmacies. There is no prescription. Insurance covers prescribed medications from licensed pharmacies, so research peptides don't enter the calculation at all. This isn't a coverage limitation that might shift; it's a categorical mismatch.

The HSA and FSA question comes up frequently and the answer is genuinely nuanced. Health Savings Account rules permit reimbursement for medical expenses that meet the IRS definition of "medical care," which includes amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease. Flexible Spending Accounts follow essentially the same rules. A compounded medication prescribed by a licensed physician for a specific medical purpose is generally considered a qualifying expense under this framework, and several tax professionals and HSA administrators have confirmed that interpretation. What matters is documentation: a valid prescription from a licensed provider in your state, a receipt from a licensed compounding pharmacy, and ideally a note in your medical record explaining the clinical rationale. You cannot use HSA funds for research peptides because they aren't medications — that use would likely be disallowed on audit. But properly documented compounded peptide prescriptions are in a meaningfully different position than people realize. Check with your HSA administrator before assuming denial.

The appeals process for off-label use of FDA-approved peptides is worth understanding because it occasionally works. Most insurance plans have a formal appeals pathway, and for off-label use of approved drugs, a strong appeal includes peer-reviewed literature supporting the use for your specific condition, a letter of medical necessity from your prescriber documenting why alternatives are inadequate, and ideally a reference to your plan documents specifying how off-label coverage is handled. Plans are legally required to respond to appeals within defined timelines. External review — where an independent organization reviews the denial — is available in most states and often results in better outcomes than internal appeals for evidence-supported medical uses. None of this is easy, and appeals take time, but for a drug that costs several hundred dollars a month and has genuine clinical literature behind it, a well-constructed appeal is worth the effort.

The honest economic reality of peptide therapy outside FDA-approved indications is that it is cash-pay. This isn't a gap that's about to close for most protocols. Simple peptide protocols — a single compounded peptide at moderate doses — typically run $50 to $150 per month depending on the compound and pharmacy. Intermediate protocols involving two or three compounds run $200 to $400 per month. Sophisticated multi-peptide protocols at higher doses, particularly those involving growth hormone secretagogues with regular IGF-1 monitoring and follow-up appointments, can reach $500 to $1,000 or more per month when you include clinical oversight. The clinical oversight component is itself usually cash-pay at practices that specialize in this work, since many don't participate in insurance networks.

None of this means peptide therapy is categorically unaffordable or not worth pursuing. It means going in with accurate cost expectations rather than hoping insurance will step in. If you're considering a protocol, building the full monthly cost — medication plus clinical oversight plus labs — into your budget before you start is the only honest way to evaluate whether it's sustainable. Labs are sometimes covered by your insurance as general wellness or diagnostic testing when ordered by an in-network provider, which can reduce that component of ongoing cost. The medication itself is the part that's almost certainly cash-pay.

The path with the most financial leverage — and the clearest legal footing — is a protocol involving an FDA-approved drug at an FDA-approved indication, prescribed through a standard pharmacy, with your insurer in the loop from the start. That's not available for most of what the peptide therapy space offers. Where you're working outside that framework, HSA documentation and a realistic monthly budget are the practical tools available to you.